187 related articles for article (PubMed ID: 38091210)
1. Neuromyelitis optica associated with the use of Atezolizumab in a patient with advanced lung adenocarcinoma.
Pedrero Prieto M; Gorriz Romero D; Gómez Roch E; Pérez Miralles FC; Casanova Estruch B
Neurol Sci; 2024 May; 45(5):2199-2202. PubMed ID: 38091210
[TBL] [Abstract][Full Text] [Related]
2. A case report of neuromyelitis optica spectrum disorder induced by pembrolizumab treatment for lung adenocarcinoma: a clinical and immunohistochemical study.
Hirano S; Kojima A; Nakayama Y; Takeda T; Kishimoto T; Takahashi T; Kuwabara S; Mori M
BMC Neurol; 2022 Dec; 22(1):483. PubMed ID: 36517738
[TBL] [Abstract][Full Text] [Related]
3. Neuromyelitis optica spectrum disorder after treatment with pembrolizumab.
Shimada T; Hoshino Y; Tsunemi T; Hattori A; Nakagawa E; Yokoyama K; Hattori N
Mult Scler Relat Disord; 2020 Jan; 37():101447. PubMed ID: 31655267
[TBL] [Abstract][Full Text] [Related]
4. Neuromyelitis optica spectrum disorders in South of Tunisia: A rare entity with low seroprevalence of anti-aquaporin 4 autoantibodies.
Mejdoub S; Feki S; Dammak M; Farhat N; Hdiji O; Boukthir S; Hachicha H; Mhiri C; Masmoudi H
Rev Neurol (Paris); 2020 May; 176(4):261-267. PubMed ID: 31668529
[TBL] [Abstract][Full Text] [Related]
5. Seropositive Neuromyelitis Optica in a Case of Undiagnosed Ankylosing Spondylitis: A Neuro-Rheumatological Conundrum.
Ghosh Md R; Roy D; León-Ruiz M; Das S; Dubey S; Benito-León J
Qatar Med J; 2022; 2022(3):29. PubMed ID: 35864917
[TBL] [Abstract][Full Text] [Related]
6. Neuromyelitis optica spectrum disorders with antibodies to myelin oligodendrocyte glycoprotein or aquaporin-4: Clinical and paraclinical characteristics in Algerian patients.
Bouzar M; Daoudi S; Hattab S; Bouzar AA; Deiva K; Wildemann B; Reindl M; Jarius S
J Neurol Sci; 2017 Oct; 381():240-244. PubMed ID: 28991690
[TBL] [Abstract][Full Text] [Related]
7. Early B cell tolerance defects in neuromyelitis optica favour anti-AQP4 autoantibody production.
Cotzomi E; Stathopoulos P; Lee CS; Ritchie AM; Soltys JN; Delmotte FR; Oe T; Sng J; Jiang R; Ma AK; Vander Heiden JA; Kleinstein SH; Levy M; Bennett JL; Meffre E; O'Connor KC
Brain; 2019 Jun; 142(6):1598-1615. PubMed ID: 31056665
[TBL] [Abstract][Full Text] [Related]
8. Neuromyelitis optica spectrum disorder: do patients positive and negative for anti-aquaporin-4 antibodies present distinct entities? A Colombian perspective.
Ortiz Salas PA; Gaviria Carrillo M; Cortés Bernal GA; Moreno Medina K; Roa LF; Rodríguez Quintana JH
Neurologia (Engl Ed); 2023 Sep; 38(7):504-510. PubMed ID: 35637138
[TBL] [Abstract][Full Text] [Related]
9. [Transverse myelitis syndrom as a result of neuromyelitis optica spectrum disorders, systemic lupus erythematosus and myasthenia gravis combination].
Topuzova MP; Bisaga GN; Alekseeva TM; Isabekova PS; Сhaykovskaya AD; Panina EB; Pavlova TA; Ternovykh IK
Zh Nevrol Psikhiatr Im S S Korsakova; 2020; 120(7. Vyp. 2):97-106. PubMed ID: 32844638
[TBL] [Abstract][Full Text] [Related]
10. Clinical and paraclinical profile of neuromyelitis optic spectrum disorder in a peruvian cohort.
Castro-Suarez S; Guevara-Silva E; Osorio-Marcatinco V; Alvarez-Toledo K; Meza-Vega M; Caparó-Zamalloa C
Mult Scler Relat Disord; 2022 Aug; 64():103919. PubMed ID: 35691236
[TBL] [Abstract][Full Text] [Related]
11. Clinical characteristics of late-onset neuromyelitis optica spectrum disorder.
Min W; Zhang L; Wang S; Xue M; Guo C; Zhu M
Mult Scler Relat Disord; 2023 Feb; 70():104517. PubMed ID: 36708681
[TBL] [Abstract][Full Text] [Related]
12. Neuromyelitis optica spectrum disorder as a paraneoplastic manifestation of lung adenocarcinoma expressing aquaporin-4.
Iorio R; Rindi G; Erra C; Damato V; Ferilli M; Sabatelli M
Mult Scler; 2015 May; 21(6):791-4. PubMed ID: 25716881
[TBL] [Abstract][Full Text] [Related]
13. Inebilizumab: A Review in Neuromyelitis Optica Spectrum Disorder.
Nie T; Blair HA
CNS Drugs; 2022 Oct; 36(10):1133-1141. PubMed ID: 36070074
[TBL] [Abstract][Full Text] [Related]
14. Prevalence of anti-aquaporin 4 antibody in a diagnostic cohort of patients being investigated for possible neuromyelitis optica spectrum disorder in Western Australia.
Fabis-Pedrini MJ; Bundell C; Wee CK; Lucas M; McLean-Tooke A; Mastaglia FL; Carroll WM; Kermode AG
J Neuroimmunol; 2018 Nov; 324():76-80. PubMed ID: 30248527
[TBL] [Abstract][Full Text] [Related]
15. Neuromyelitis optica spectrum disorder secondary to treatment with anti-PD-1 antibody nivolumab: the first report.
Narumi Y; Yoshida R; Minami Y; Yamamoto Y; Takeguchi S; Kano K; Takahashi K; Saito T; Sawada J; Terui H; Katayama T; Sasaki T; Ohsaki Y
BMC Cancer; 2018 Jan; 18(1):95. PubMed ID: 29361915
[TBL] [Abstract][Full Text] [Related]
16. Update on the diagnosis and treatment of neuromyelitis optica spectrum disorders (NMOSD) - revised recommendations of the Neuromyelitis Optica Study Group (NEMOS). Part II: Attack therapy and long-term management.
Kümpfel T; Giglhuber K; Aktas O; Ayzenberg I; Bellmann-Strobl J; Häußler V; Havla J; Hellwig K; Hümmert MW; Jarius S; Kleiter I; Klotz L; Krumbholz M; Paul F; Ringelstein M; Ruprecht K; Senel M; Stellmann JP; Bergh FT; Trebst C; Tumani H; Warnke C; Wildemann B; Berthele A;
J Neurol; 2024 Jan; 271(1):141-176. PubMed ID: 37676297
[TBL] [Abstract][Full Text] [Related]
17. Clinical profile of patients with paraneoplastic neuromyelitis optica spectrum disorder and aquaporin-4 antibodies.
Sepúlveda M; Sola-Valls N; Escudero D; Rojc B; Barón M; Hernández-Echebarría L; Gómez B; Dalmau J; Saiz A; Graus F
Mult Scler; 2018 Nov; 24(13):1753-1759. PubMed ID: 28920766
[TBL] [Abstract][Full Text] [Related]
18. Neuromyelitis optica spectrum disorder with lung adenocarcinoma and intraductal papillary mucinous neoplasm.
Fang W; Zheng Y; Cai MT; Zhang YX
Mult Scler Relat Disord; 2019 Jul; 32():77-80. PubMed ID: 31060025
[TBL] [Abstract][Full Text] [Related]
19. Satralizumab: A Review in Neuromyelitis Optica Spectrum Disorder.
Fung S; Shirley M
CNS Drugs; 2023 Apr; 37(4):363-370. PubMed ID: 36933107
[TBL] [Abstract][Full Text] [Related]
20. Neuromyelitis optica spectrum disorders: from pathophysiology to therapeutic strategies.
Carnero Contentti E; Correale J
J Neuroinflammation; 2021 Sep; 18(1):208. PubMed ID: 34530847
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
